Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Pancreatic cancer

Oncology and palliative care · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Cholangitis or gastric obstruction

Fever, rigors, jaundice and hypotension suggest infected biliary obstruction, while persistent vomiting may signal duodenal obstruction.

Action: Resuscitate and give antibiotics for sepsis, obtain urgent biliary and pancreatic specialist input, and arrange source control with endoscopic or percutaneous drainage without delaying for a complete elective staging sequence.

Synopsis

Recognise obstructive jaundice and other pancreatic-cancer patterns, stage resectability before intervention, obtain tissue before systemic treatment when required and coordinate biliary drainage, surgery, chemotherapy and supportive care safely.

  • Obstructive jaundice is a pivotal clue in Pancreatic cancer: Painless jaundice with pale stool, dark urine and pruritus is typical of a pancreatic-head tumour and requires an urgent cancer pathway.
  • Immediate priority in unstable Pancreatic cancer: Resuscitate and give antibiotics for sepsis, obtain urgent biliary and pancreatic specialist input, and arrange source control with endoscopic or percutaneous drainage without delaying for a complete elective staging sequence.
  • Pancreatic-protocol contrast CT is used early to define tumour, arterial and venous relations, liver and peritoneal metastases and resectability before biliary intervention where stable. This is the first-line staging examination in suspected pancreatic cancer; specialist MDT review, not the report phrase alone, determines resectability.
  • MRI with MRCP refines the next decision because use selectively for problem solving and staging; it complements rather than routinely replaces high-quality pancreatic-protocol CT.
  • Stage before disturbing anatomy: Obtain pancreatic-protocol CT before biliary drainage when clinically safe, then review resectability at a specialist hepatopancreatobiliary MDT.
  • Relieve biliary obstruction selectively: Prefer a self-expanding metal stent when durable palliation or neoadjuvant treatment is expected, using MDT-specific device planning.
  • A major avoidable harm is biliary sepsis; Obstructed or instrumented ducts can become infected, causing septic shock and requiring antibiotics plus urgent drainage.
  • A common diagnostic trap is distal cholangiocarcinoma: Both cause painless obstructive jaundice; duct-centred imaging, endoscopy and histopathology distinguish treatment pathways.

Key red flags

Painless progressive jaundice, dark urine, pale stool and pruritus suggest distal malignant biliary obstruction.

Unexplained weight loss, epigastric pain radiating to the back or new anorexia persists in an older adult.

New diabetes, rapidly worsening glycaemia or pancreatitis occurs without another clear explanation.

Fever, rigors, hypotension or confusion accompanies jaundice and indicates possible acute cholangitis.

Persistent vomiting, early satiety or inability to tolerate intake suggests gastric outlet obstruction.

A tender calf, pulmonary embolus or migratory thrombophlebitis may be a thrombotic presentation of occult cancer.

Cholangitis

Fever, rigors, jaundice, hypotension or confusion with obstruction is a source-control emergency rather than routine outpatient staging.

Investigation priorities

01
Pancreatic-protocol contrast CTFirst step

Define tumour, arterial and venous relations, liver and peritoneal metastases and resectability before biliary intervention where stable.

Management branches

DiagnoseStage before disturbing anatomy

Pancreatic cancer is suspected in a stable patient with jaundice, pain, weight loss or a pancreatic lesion.

  1. Obtain pancreatic-protocol CT before biliary drainage when clinically safe, then review resectability at a specialist hepatopancreatobiliary MDT.
  2. Use MRI for liver or duct uncertainty and endoscopic ultrasound core biopsy when neoadjuvant, systemic or non-operative treatment is planned.
  3. Assess performance, nutrition, diabetes, exocrine insufficiency, thrombosis and hereditary features alongside anatomical staging.

Key medicines

Pancreatin replacementStart a high-strength preparation with all meals and snacks; a common adult starting dose supplies at least 50,000 units of lipase with a main meal and 25,000 units with a snack, titrated to stool, weight and intake.Take during food and spread capsules through longer meals; increase to dietary fat and consider acid suppression if response remains poor, while checking adherence and alternative diarrhoea causes.
Modified FOLFIRINOXA common 14-day specialist regimen uses oxaliplatin 85 mg/m² IV, irinotecan 150 mg/m² IV, folinic acid 400 mg/m² IV and fluorouracil 2,400 mg/m² by 46-hour continuous infusion, with protocol-led dose modification.Requires central access and oncology prescribing; monitor marrow, diarrhoea, cholinergic toxicity, mucositis, neuropathy, liver function, DPD status and infection, with dose changes for frailty and organ dysfunction.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG85 pancreatic cancer in adultsCurrent NICE recommendations for pancreatic cancer in adults assessment and treatment.
  • NICE QS177 pancreatic cancer quality standardQuality statements for specialist diagnosis, staging, treatment and support in pancreatic cancer.
  • Royal College of Pathologists cancer datasetsUK pathology sampling, staging, margin and molecular reporting standards.
  • BNF pancreatin, gemcitabine and morphineUK prescribing, contraindication and monitoring information for pancreatin, gemcitabine and morphine.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom